Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2014

01-06-2014 | Research Article

p53 pathway activation by telomere attrition in X-DC primary fibroblasts occurs in the absence of ribosome biogenesis failure and as a consequence of DNA damage

Authors: J. Carrillo, A. González, C. Manguán-García, L. Pintado-Berninches, R. Perona

Published in: Clinical and Translational Oncology | Issue 6/2014

Login to get access

Abstract

Background

Dyskeratosis congenita (DC) is a rare inherited bone marrow failure syndrome with high clinical heterogeneity. Various mutations have been reported in DC patients, affecting genes that code for components of H/ACA ribonucleoproteins, proteins of the telomerase complex and components of the shelterin complex.

Objectives

We aim to clarify the role of ribosome biogenesis failure in senescence induction in X-DC since some studies in animal models have reported a decrease in ribosome biogenesis as a major role in the disease.

Methods

Dyskerin was depleted in normal human fibroblasts by expressing two DKC1 shRNAs. Common changes in gene expression profile between these dyskerin-depleted cells and X-DC fibroblasts were analyzed.

Results

Dyskerin depletion induced early activation of the p53 pathway probably secondary to ribosome biogenesis failure. However, the p53 pathway in the fibroblasts from X-DC patients was activated only after an equivalent number of passes to AD-DC fibroblasts, in which telomere attrition in each division rendered shorter telomeres than control fibroblasts. Indeed, no induction of DNA damage was observed in dyskerin-depleted fibroblasts in contrast to X-DC or AD-DC fibroblasts suggesting that DNA damage induced by telomere attrition is responsible for p53 activation in X-DC and AD-DC fibroblasts. Moreover, p53 depletion in senescent DC fibroblasts rescued their proliferative capacity and reverted the morphological changes produced after prolonged culture.

Conclusions

Our data indicate that ribosome biogenesis do not seem to play an important role in dyskeratosis congenita, conversely increasing DNA damage and activation of p53 pathway triggered by telomere shortening is the main activator of cell senescence.
Literature
4.
go back to reference Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5):447–9.PubMedCrossRef Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet. 2004;36(5):447–9.PubMedCrossRef
5.
go back to reference Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352(14):1413–24.PubMedCrossRef Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352(14):1413–24.PubMedCrossRef
6.
go back to reference Parry EM, Alder JK, Lee SS, Phillips JA, Loyd JE, Duggal P, et al. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet. 2011;48(5):327–33.PubMedCentralPubMedCrossRef Parry EM, Alder JK, Lee SS, Phillips JA, Loyd JE, Duggal P, et al. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet. 2011;48(5):327–33.PubMedCentralPubMedCrossRef
7.
go back to reference Ge J, Rudnick DA, He J, Crimmins DL, Ladenson JH, Bessler M, et al. Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. Mol Cell Biol. 2010;30(2):413–22.PubMedCentralPubMedCrossRef Ge J, Rudnick DA, He J, Crimmins DL, Ladenson JH, Bessler M, et al. Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. Mol Cell Biol. 2010;30(2):413–22.PubMedCentralPubMedCrossRef
8.
go back to reference Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003;299(5604):259–62.PubMedCrossRef Ruggero D, Grisendi S, Piazza F, Rego E, Mari F, Rao PH, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003;299(5604):259–62.PubMedCrossRef
9.
go back to reference Pereboom TC, van Weele LJ, Bondt A, MacInnes AW. A zebrafish model of dyskeratosis congenita reveals hematopoietic stem cell formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood. 2011;118(20):5458–65.PubMedCrossRef Pereboom TC, van Weele LJ, Bondt A, MacInnes AW. A zebrafish model of dyskeratosis congenita reveals hematopoietic stem cell formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood. 2011;118(20):5458–65.PubMedCrossRef
10.
go back to reference Zhang Y, Morimoto K, Danilova N, Zhang B, Lin S. Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing. PLoS One. 2012;7(1):e30188.PubMedCentralPubMedCrossRef Zhang Y, Morimoto K, Danilova N, Zhang B, Lin S. Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing. PLoS One. 2012;7(1):e30188.PubMedCentralPubMedCrossRef
11.
go back to reference Panic L, Montagne J, Cokaric M, Volarevic S. S6-Haploinsufficiency activates the p53 tumor suppressor. Cell Cycle. 2007;6(1):20–4.PubMedCrossRef Panic L, Montagne J, Cokaric M, Volarevic S. S6-Haploinsufficiency activates the p53 tumor suppressor. Cell Cycle. 2007;6(1):20–4.PubMedCrossRef
12.
go back to reference Carrillo J, Martínez P, Solera J, Moratilla C, González A, Manguán-García C, et al. High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. Blood Cells Mol Dis. 2012;49(3–4):140–6.PubMedCrossRef Carrillo J, Martínez P, Solera J, Moratilla C, González A, Manguán-García C, et al. High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. Blood Cells Mol Dis. 2012;49(3–4):140–6.PubMedCrossRef
13.
go back to reference Nagasawa H, Little JB. Suppression of cytotoxic effect of mitomycin-C by superoxide dismutase in Fanconi’s anemia and dyskeratosis congenita fibroblasts. Carcinogenesis. 1983;4:795–9.PubMedCrossRef Nagasawa H, Little JB. Suppression of cytotoxic effect of mitomycin-C by superoxide dismutase in Fanconi’s anemia and dyskeratosis congenita fibroblasts. Carcinogenesis. 1983;4:795–9.PubMedCrossRef
14.
go back to reference Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32–8.PubMedCrossRef Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32–8.PubMedCrossRef
15.
go back to reference Wong JMY, Kyasa MJ, Hutchins L, Collins K. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum Genet. 2004;115:448–55.PubMedCrossRef Wong JMY, Kyasa MJ, Hutchins L, Collins K. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum Genet. 2004;115:448–55.PubMedCrossRef
16.
go back to reference d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.PubMedCrossRef d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–8.PubMedCrossRef
18.
go back to reference d’Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 2004;18:1781–99.PubMedCrossRef d’Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 2004;18:1781–99.PubMedCrossRef
19.
go back to reference Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci. 2008;105(23):8073–8.PubMedCentralPubMedCrossRef Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci. 2008;105(23):8073–8.PubMedCentralPubMedCrossRef
20.
go back to reference Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet. 2007;16(13):1619–29.PubMedCentralPubMedCrossRef Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet. 2007;16(13):1619–29.PubMedCentralPubMedCrossRef
22.
go back to reference Machado-Pinilla R, Sanchez-Perez I, Ramon Murguia J, Sastre L, Perona R. A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. Blood. 2008;111(5):2606–14.PubMedCrossRef Machado-Pinilla R, Sanchez-Perez I, Ramon Murguia J, Sastre L, Perona R. A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. Blood. 2008;111(5):2606–14.PubMedCrossRef
23.
go back to reference Westin ER, Aykin-Burns N, Buckingham EM, Spitz DR, Goldman FD, Klingelhutz AJ. The p53/p21WAF/CIP pathway mediates oxidative stress and senescence in dyskeratosis congenita cells with telomerase insufficiency. Antioxid Redox Signal. 2011;14(6):985–97.PubMedCentralPubMedCrossRef Westin ER, Aykin-Burns N, Buckingham EM, Spitz DR, Goldman FD, Klingelhutz AJ. The p53/p21WAF/CIP pathway mediates oxidative stress and senescence in dyskeratosis congenita cells with telomerase insufficiency. Antioxid Redox Signal. 2011;14(6):985–97.PubMedCentralPubMedCrossRef
Metadata
Title
p53 pathway activation by telomere attrition in X-DC primary fibroblasts occurs in the absence of ribosome biogenesis failure and as a consequence of DNA damage
Authors
J. Carrillo
A. González
C. Manguán-García
L. Pintado-Berninches
R. Perona
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1112-3

Other articles of this Issue 6/2014

Clinical and Translational Oncology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine